CYP1A1 and malignant colon neoplasm: Specifically the studies by Sheldrake et al., Travica et al., Pors et al. and Sutherland et al. have focused on the development and optimization of novel duocarmycin analogues that are activated by CYP1A1 or CYP2W1 into potent cytotoxins, as new anticancer prodrugs for bladder or colon cancer treatment.